Abstract
SARS-CoV-2, the etiological agent of the COVID-19 pandemic, is a member of the Coron-aviridae family. It is an enveloped virus with ion channels in its membrane, the most characterized of which is the E protein. Therefore, in an attempt to identify blockers of the E channel, we screened a library of 2839 approved-for-human-use drugs. Our approach yielded eight compounds that exhibited appreciable activity in three bacteria-based channel assays. Considering the fact that the E channel is the most conserved of all SARS-CoV-2 proteins, any inhibitor of its activity may provide an option to curb the viral spread. In addition, inhibitors can also enhance our ability to understand the exact role played by the E protein during the infectivity cycle. Finally, detailed electrophysiological analyses, alongside in vitro and in vivo studies will be needed to establish the exact potential of each of the blockers identified in our study.
| Original language | English |
|---|---|
| Article number | 604 |
| Journal | Pharmaceuticals |
| Volume | 14 |
| Issue number | 7 |
| DOIs | |
| State | Published - 23 Jun 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antiviral drugs
- Bacterial assays
- COVID-19
- Channel blockers
- Viral channels
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Pharmaceutical Science
- Drug Discovery
Fingerprint
Dive into the research topics of 'Identification of sars-cov-2 e channel blockers from a repurposed drug library'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver